CLGN News and Press, CollPlant Holdings Ltd. From 05/24/23

2023-05-24 12:49:08 ET CollPlant Biotechnologies Ltd. (CLGN) Q1 2023 Earnings Conference Call May 24, 2023, 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants ...

2023-05-24 07:29:42 ET CollPlant Biotechnologies press release ( NASDAQ: CLGN ): Q1 Non-GAAP EPS of -$0.29. Revenue of $0.43M. For further details see: CollPlant Biotechnologies Non-GAAP EPS of -$0.29, revenue of $0.43M

CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update PR Newswire Strong positive sales trajectory for rhCollagen based products Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tis...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION PR Newswire -  Conference call to be held on May 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 2, 2023 /PRNewswire/ -- Col...

Joint development and commercialization agreement will initially focus on development of bioprinting solution for CollPlant’s regenerative breast implants, addressing $2.6 billion market opportunity Stratasys’ P3 technology-based bioprinter and CollPlant’s...

2023-03-29 12:28:03 ET CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Conference Call March 29, 2023 10:00 a.m. ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Chief Financial Officer Confer...

2023-03-29 07:06:15 ET CollPlant press release ( NASDAQ: CLGN ): FY GAAP EPS of -$1.53 beats by $0.03 . Revenue of $0.3M (-98.1% Y/Y) in-line. Cash, cash equivalents and short-term deposits as of December 31, 2022, were $29.7 million (excluding restr...

Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update PR Newswire Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen ...

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION PR Newswire - Conference call to be held on March 29, 2023 at 10:00 am U.S. EDT - REHOVOT, Israel , March 14, 2023 /PRNewswire/ -- CollPlant ...

Summary Possesses only plant-based collagen product with multiple end-market opportunities. AbbVie relationship alone justifies the current valuation. The company's cap is a mere $120 million and debt free. Business models include upfront and milestone payments and ultimately ro...